FIELD: pharmaceutics.
SUBSTANCE: group of inventions refers to the chemical and pharmaceutical industry and presents a delayed-release dosage form including particle with core and core coating, where the core contains the drug, and the coating comprises mixture of the first substance sensitive to exposure to colon bacteria and the second substance being a film-forming polymer substance with pH limit at pH 6.5 or higher, wherein the first substance comprises polysaccharide selected from group consisting of amylopectin, chitosan, chondroitin sulfate, cyclodextrin, dextran and carrageenan. Group of inventions also includes a method of preparing the dosage form described above and a method for targeted delivery of the drug to the colon.
EFFECT: inventions allow sustained release of the active substance in the colon, thereby achieving more accurate and reliable delivery of the drug to the intestine.
26 cl, 17 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG FORM FOR DELIVERY OF MEDICATION INTO LARGE INTESTINE | 2007 |
|
RU2478372C2 |
| COATING COMPOSITION CONTAINING STARCH | 2007 |
|
RU2440104C2 |
| FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN INTESTINE | 2016 |
|
RU2681315C2 |
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
| COMPOSITION EXHIBITING THE DELAYED (PROLONGED) RELEASING | 1990 |
|
RU2093148C1 |
| ORAL CHOLESTYRAMINE COMPOSITION AND APPLICATION THEREOF | 2017 |
|
RU2750944C2 |
| CHOLESTYRAMINE PELLETS, ORAL CHOLESTYRAMINE COMPOSITIONS AND THEIR USE | 2018 |
|
RU2782016C2 |
| PHARMACEUTICAL MEDICINAL FORM, RESISTANT TO GASTRIC JUICE ACTIVITY, WHICH INCLUDES N-(2-(2-PHTHALIMIDOETOXY)ACETYL)-L-ALANYL-D-GLUTAMIC ACID (LK 423) | 2005 |
|
RU2375047C2 |
| MEDICINAL FORMS ON BASIS OF BIPHOSPHONATES | 2005 |
|
RU2359678C2 |
| CROSS-LINKED HIGH-AMYLOSE STARCH FOR USING IN PHARMACEUTICAL COMPOSITION WITH SUSTAINED-RELEASING AND METHOD FOR ITS PREPARING | 2001 |
|
RU2274443C2 |
